Abstract:OBJECTIVE:To evaluate the value of human epididymis secretory protein 4 (HE4) and CA(125) in the diagnosis of ovarian malignancy.METHODS:HE4 and CA(125) in the serum specimens of malignant ovarian tumor group (30 cases), benign ovarian diseases (110 cases; 45 benign ovarian tumor, 57 endometriotic diseases and 8 pelvic inflammation were included) and healthy women group (137 cases) were assayed double blindly. The levels and the diagnosis efficiency of the HE4 and CA(125) were analyzed.RESULTS:(1) The median levels of HE4 and CA(125) were significantly higher in malignant ovarian tumor group (244 pmol/L and 601 kU/L respectively) than those of the benign ovarian diseases group (32 pmol/L and 22 kU/L respectively) and healthy women group (32 pmol/L and 11 kU/L respectively) (P = 0.000 - 0.029). The median levels of CA(125) were also higher in endometriotic diseases and pelvic inflammation groups (53 and 41 kU/L respectively) than those of benign ovarian tumor group and healthy women group (12 and 11 kU/L respectively; P = 0.000 - 0.031). (2) The positive rate of HE4 was lower than that of CA(125) in malignant ovarian tumor group (P = 0.036). HE4 was negative in benign diseases and healthy women groups. But the positive rates of CA(125) were 56.1% and 5/8 respectively in endometriotic diseases and pelvic inflammation groups and there were significant differences compared with HE4 (P = 0.000). (3) The HE4 assay had advantage over the CA(125) assay in receiver operating characteristic-area under the curve (ROC-AUC) and sensitivity with a specificity of 100% when ovarian malignancy was compared with controls having benign diseases and healthy women, benign tumor or benign diseases groups respectively. The CA(125) assay had advantage over the HE4 assay in ROC-AUC and sensitivity with the same specificity when ovarian cancers were compared with controls having healthy women group. (4) Combined assay of HE4 and CA(125) was better than CA(125) alone when ovarian malignancy was compared with controls having any group. (5) Combined assay was better than HE4 alone in ROC-AUC and sensitivity with the same specificity when ovarian cancers were compared with controls having benign diseases and healthy women or healthy women groups. And combined assay was lower in the ROC-AUC and the sensitivity with specificity of 100% than HE4 when ovarian cancers were compared with controls having benign tumors or benign diseases groups respectively. (6) The diagnosis efficiency of the HE4 assay at the level 86 pmol/L determined in ROC curve with controls having benign diseases and healthy women group and at the 95% reference level 50 pmol/L of healthy women or 150 pmol/L recommended by the kit respectively was compared. The sensitivity of 50 pmol/L was 73% higher than 150 pmol/L and 86 pmol/L, while the specificity and positive predictive value were lower (P = 0.002, P = 0.000). The specificity, accuracy and positive predictive value of HE4 assay at the set point of 150 pmol/L and 86 pmol/L were 100%, 96% and 96%. The set point of 86 pmol/L had advantage over 150 pmol/L at the sensitivity of diagnosis, 70% and 63% respectively. But the positive predictive value was 95% lower than 150 pmol/L, being 100%. There was no significant difference (P = 0.883, P = 0.883).CONCLUSIONS:The specificity of HE4 assay is higher than CA(125) assay in the diagnosis of ovarian cancer and HE4 combined with CA(125) assay can improve the diagnoses. The set point of 150 pmol/L is advantageous for the accurate diagnosis, while the set point of 86 pmol/L is advantageous for the screening of malignant ovarian cancer.

Serum HE4 As a Useful Biomarker in Discriminating Ovarian Cancer from Benign Pelvic Disease

Diagnostic Performance of HE4 and ROMA among Chinese Women.

HE4 as a biomarker for ovarian and endometrial cancer management.

Human Epididymis Protein 4 (He4) As A Serum Tumor Biomarker In Patients With Ovarian Carcinoma

The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass

HE4 As a Serum Biomarker for ROMA Prediction and Prognosis of Epithelial Ovarian Cancer

Expression of Serum Human Epididymis Protein 4 in Epithelial Ovarian Cancer and Its Correlation with Prognosis

Serum CA125 and HE4 as Biomarkers for the Detection of Endometrial Cancer and Associated High-Risk Features

[Measurement of Serum Human Epididymis Secretory Protein 4 Combined with CA125 Assay in Differential Diagnosis of Endometriosis Cyst and Ovarian Benign and Malignant Tumors].

Serum Human Epididymis Protein 4 Vs. Carbohydrate Antigen 125 and Their Combination for Endometrial Cancer Diagnosis: a Meta-Analysis.

[The Values of Serum Human Epididymis Secretory Protein 4 and CA(125) Assay in the Diagnosis of Ovarian Malignancy].

Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis

Studies on the Value of Human Epididymis Protein 4 in Patients with Ovarian Cancer

The role of novel biomarker HE4 in endometrial cancer: a case control prospective study

Values of human epididymis protein 4 combined with carbohydrate antigen 125 in diagnosis of human ovarian cancer and ovarian benign tumors

The values of serunl human epididymis secretory protein 4 and CA125 assay in the diagnosis of ovarian malignancy

Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors

The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma

The value of serum CA125, HE4 and imaging examinations in detecting the recurrence of ;postoperative ovarian cancer

[Clinical value of combined detection of serum human epididymal secretory protein E4 and CA(125) in the diagnosis of endometrial carcinoma]

Diagnostic Values in Ovarian Cancer with the Measurement of Serum Human Epididymis Secretory Protein 4 Combined with CA125 and Osteopontin